European OTC Switch Still Muted By Regulatory Resistance
This article was originally published in The Pink Sheet Daily
Executive Summary
OTC sales growth is stifled by the EU’s “extremely restricted” switch evaluation process, says AESGP Director General Hubertus Cranz. But while prescription revenues shrink as governments tighten budgets, the OTC market is not hampered in this way.